BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31255914)

  • 1. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
    J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
    Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
    Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases.
    Elliott J; Suessmuth Y; Scott LM; Nahlik K; McMullin MF; Constantinescu SN; Green AR; Johnston JA
    Haematologica; 2009 Apr; 94(4):576-80. PubMed ID: 19229050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
    Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
    Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
    Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
    Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
    Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
    Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
    Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.
    Suessmuth Y; Elliott J; Percy MJ; Inami M; Attal H; Harrison CN; Inokuchi K; McMullin MF; Johnston JA
    Br J Haematol; 2009 Nov; 147(4):450-8. PubMed ID: 19735488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.
    Dusa A; Staerk J; Elliott J; Pecquet C; Poirel HA; Johnston JA; Constantinescu SN
    J Biol Chem; 2008 May; 283(19):12941-8. PubMed ID: 18326042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2, the JAK2 V617F mutant and cytokine receptors.
    Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
    Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
    Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
    Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sympathomimetic agonist mirabegron did not lower
    Drexler B; Passweg JR; Tzankov A; Bigler M; Theocharides AP; Cantoni N; Keller P; Stussi G; Ruefer A; Benz R; Favre G; Lundberg P; Nienhold R; Fuhrer A; Biaggi C; Manz MG; Bargetzi M; Mendez-Ferrer S; Skoda RC;
    Haematologica; 2019 Apr; 104(4):710-716. PubMed ID: 30409796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.
    Lu X; Huang LJ; Lodish HF
    J Biol Chem; 2008 Feb; 283(9):5258-66. PubMed ID: 18158285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
    Gorantla SP; Dechow TN; Grundler R; Illert AL; Zum Büschenfelde CM; Kremer M; Peschel C; Duyster J
    Blood; 2010 Nov; 116(22):4600-11. PubMed ID: 20696946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.